Enlivex (ENLV) Price & Analysis

Compare

493 Followers

ENLV Stock Chart & Stats

$0.93

-$0.07(-5.60%)

At close: Jan 08 4:00 PM EST

$0.93

-$0.07(-5.60%)

Day’s Range― - ―

52-Week Range$0.66 - $2.10

Previous CloseN/A

Volume59.48K

Average Volume (3M)182.02K

Market Cap

$229.43M

Enterprise Value$2.89M

Total Cash (Recent Filing)$18.32M

Total Debt (Recent Filing)$701.00K

Price to Earnings (P/E)―

Beta1.05

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding237,381,500

10 Day Avg. Volume216,695

30 Day Avg. Volume182,016

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.02

Price to Sales (P/S)0.00

P/FCF Ratio-1.83

Enterprise Value/Market Cap0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-9.90

Enterprise Value/Ebitda-0.21

Forecast

1Y Price Target

$13.00

Price Target Upside1297.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPositive three-month top-line data from the Phase 2a stage of a multi-center, two-stage Phase 1/2 double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee OA were recently reported.

Development And PartnershipsEnlivex is advancing Allocetra toward late-stage development with a planned roadmap of catalysts, including potential regulatory approval and dosing of the first patient in Phase 2b trial.

Intellectual PropertyEnlivex recently announced the issuance of an Israeli patent entitled 'Therapeutic Apoptotic Cells for Treatment of Osteoarthritis', providing added intellectual property protection in Israel through at least 2040.

Bears Say

Enlivex News

Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Enlivex Therapeutics (ENLV) to $13 from $7 and keeps a...

5d ago

ENLV

Enlivex says RAIN token listed on KuCoin crypto exchange

Enlivex Therapeutics (ENLV) reported that its treasury asset, the RAIN token, has been listed on the KuCoin cryptocurrency...

9d ago

ENLV

Enlivex Therapeutics files to sell 212M ordinary shares for holders

16:39 EST Enlivex Therapeutics (ENLV) files to sell 212M ordinary shares for holders Published first on TheFly –...

24d ago

ENLV

Enlivex Lists RAIN Treasury Token on KuCoin to Deepen Liquidity and Market Access

Enlivex ( ($ENLV) ) has shared an update. On January 7, 2026, Enlivex Therapeutics announced that its primary...

9d ago

ENLV

Enlivex Calls February 2026 Extraordinary Meeting to Approve Governance Changes and Reverse Share Split

An announcement from Enlivex ( ($ENLV) ) is now available. On December 18, 2025, Enlivex Therapeutics announced it...

29d ago

ENLV

Enlivex Announces Fireside Chat on RAIN Token and Allocetra Development

Enlivex ( ($ENLV) ) has issued an announcement. On December 4, 2025, Enlivex Therapeutics announced a virtual fireside...

1M ago

ENLV

Enlivex Completes $212 Million Private Placement, Expands Digital Asset Strategy

Enlivex ( ($ENLV) ) just unveiled an announcement. On November 24, 2025, Enlivex Therapeutics Ltd. completed a $212...

2M ago

ENLV

Enlivex Therapeutics closes $212M private placement

Enlivex Therapeutics (ENLV) announced the closing of the Company’s previously announced $212,000,000 private investment. Enlivex intends to use...

2M ago

ENLV

3 Penny Stocks to Watch Now, 11/25/25

Antelope Enterprise Holdings, Enlivex Therapeutics, and Inno Holdings are the 3 Penny Stocks to watch on November 25, 2025, based...

2M ago

AEHL

ENLV

Crypto Currents: Upbit plans IPO, Revolut hits $75B valuation

South Korean exchange Upbit is eyeing a U.S. listing, while JPMorgan sees major upside for bitcoin miners pivoting...

2M ago

Enlivex Reports Positive Six-Month Data for Knee Osteoarthritis Trial

The latest announcement is out from Enlivex ( ($ENLV) ). Enlivex Therapeutics Ltd. announced positive six-month topline data...

2M ago

ENLV

Enlivex Completes Private Placement to Fund Digital Asset Strategy

The latest announcement is out from Enlivex ( ($ENLV) ). On November 24, 2025, Enlivex Therapeutics Ltd. announced...

2M ago

ENLV

Enlivex Therapeutics downgraded to Hold from Buy at D. Boral Capital

D. Boral Capital downgraded Enlivex Therapeutics (ENLV) to Hold from Buy with no price target after the company...

2M ago

ENLV

Enlivex Therapeutics prices 212M shares at $1.00 in private placement

Enlivex Therapeutics (ENLV) entered into a securities purchase agreement for a private investment in public equity for the...

2M ago

ENLV

ENLV FAQ

What was Enlivex Therapeutics Ltd’s price range in the past 12 months?

Enlivex Therapeutics Ltd lowest stock price was $0.66 and its highest was $2.10 in the past 12 months.

What is Enlivex Therapeutics Ltd’s market cap?

Enlivex Therapeutics Ltd’s market cap is $229.43M.

When is Enlivex Therapeutics Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Enlivex Therapeutics Ltd’s earnings last quarter?

Currently, no data Available

Is Enlivex Therapeutics Ltd overvalued?

According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enlivex Therapeutics Ltd pay dividends?

Enlivex Therapeutics Ltd does not currently pay dividends.

What is Enlivex Therapeutics Ltd’s EPS estimate?

Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enlivex Therapeutics Ltd have?

Enlivex Therapeutics Ltd has 237,381,500 shares outstanding.

What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?

Currently, no hedge funds are holding shares in ENLV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Enlivex Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.64%

Trailing 12-Months

Asset Growth

-29.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex (ENLV) Earnings & Revenues

Historic Earnings Reports

ENLV Stock 12 Month Forecast

Average Price Target

$13.00

▲(1297.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","-1":"-$1","2.75":"$2.75","6.5":"$6.5","10.25":"$10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.75,6.5,10.25,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.703,1.648923076923077,2.594846153846154,3.540769230769231,4.486692307692308,5.432615384615385,6.378538461538462,7.324461538461539,8.270384615384616,9.216307692307693,10.162230769230769,11.108153846153845,12.054076923076924,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.703,1.648923076923077,2.594846153846154,3.540769230769231,4.486692307692308,5.432615384615385,6.378538461538462,7.324461538461539,8.270384615384616,9.216307692307693,10.162230769230769,11.108153846153845,12.054076923076924,{"y":13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.703,1.648923076923077,2.594846153846154,3.540769230769231,4.486692307692308,5.432615384615385,6.378538461538462,7.324461538461539,8.270384615384616,9.216307692307693,10.162230769230769,11.108153846153845,12.054076923076924,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.17,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.919,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.703,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >